Kuros Biosciences Reports First Half of 2024 Results
Financial Highlights Direct MagnetOs™ sales increased by 159% to CHF 31.6 million from CHF 12.2 million in H1 2023; th…
Financial Highlights Direct MagnetOs™ sales increased by 159% to CHF 31.6 million from CHF 12.2 million in H1 2023; th…
The recent Implant Solutions World Summit took place over three days in Miami, Florida and brought together more than 60…
Financial Highlights Direct MagnetOs sales rose by 155% to CHF 13.9 million in Q1 2024 from CHF 5.4 million in Q1 2023…
Die pi3g GmbH & Co. KG führt auf der PiCockpit.com Plattform mit dem Terminal und dem Datei-Editor zwei neue webbasierte…
Financial highlights Direct MagnetOs sales grew by 163% to CHF 31.7 million in 2023, climbing from CHF 12.1 million…
MagnetOs™ Granules becomes the third product in the MagnetOs portfolio to receive FDA clearance to market for inter…
. New level 1 data from the MAXA Clinical Trial comparing standalone MagnetOs to the gold standard autograft in the ch…
. Financial highlights Direct sales of MagnetOs rose 75% from CHF 6.9 million to CHF 12.1 million in 2022. Total reven…
Der aktuelle Fachkräftemangel macht auch vor der IT-Branche nicht halt und gute IT-Spezialisten werden vielerorts gesuch…
Financial highlights CHF 29.4 million cash & cash equivalents, trade and other receivables as of June 30, 2022 Product…